Ropinirole

Ropinirole
Clinical data
Trade names	Requip, Repreve, Ronirol, others
Other names	SK&F-101468; SK&F101468; SKF-101468; SKF101468
AHFS/Drugs.com	Monograph
MedlinePlus	a698013
License data	US DailyMed: Ropinirole;
Routes of; administration	By mouth
ATC code	N04BC04 (WHO) ; QV03AB96 (WHO);
Legal status
Legal status	BR: Class C1 (Other controlled substances); US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	50%
Metabolism	Liver (CYP1A2)
Elimination half-life	5-6 hours
Identifiers
	IUPAC name 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one;
CAS Number	91374-21-9 ;
PubChem CID	5095;
IUPHAR/BPS	7295;
DrugBank	DB00268 ;
ChemSpider	4916 ;
UNII	030PYR8953;
KEGG	D08489 ;
ChEBI	CHEBI:8888 ;
ChEMBL	ChEMBL589 ;
CompTox Dashboard (EPA)	DTXSID8045195 ;
ECHA InfoCard	100.110.353
Chemical and physical data
Formula	C16H24N2O
Molar mass	260.381 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2Nc1cccc(c1C2)CCN(CCC)CCC;
	InChI InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19) ; Key:UHSKFQJFRQCDBE-UHFFFAOYSA-N ;
	(verify)

Ropinirole, sold under the brand name Requip among others, is a medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). It is taken by mouth.

Common side effects include sleepiness, vomiting, and dizziness. Serious side effects may include pathological gambling, hypersexuality, low blood pressure with standing and hallucinations. Use in pregnancy and breastfeeding is of unclear safety. It is a dopamine agonist and works by triggering dopamine D₂ receptors.

It was approved for medical use in the United States in 1997. It is available as a generic medication. In 2023, it was the 212th most commonly prescribed medication in the United States, with more than 2 million prescriptions.